Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
  • A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
  • A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2205/00—General characteristics of the apparatus
  • A61M2205/27—General characteristics of the apparatus preventing use
  • A61M2205/273—General characteristics of the apparatus preventing use preventing reuse, e.g. of disposables
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2205/00—General characteristics of the apparatus
  • A61M2205/27—General characteristics of the apparatus preventing use
  • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2205/00—General characteristics of the apparatus
  • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
  • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback

Definitions

• This disclosure relates to a cap for a drug delivery device and drug delivery device comprising the cap.
• a cap is provided for covering at least parts of the device. In this way, internal components of the device can be prevented from
• a drug delivery device is described in documents WO 2008/058666 A1 and
• the cap may be adapted and arranged to cover a dispensing end of the device.
• the cap may comprise
• the cap may comprise at least one indication element.
• the cap may comprise two or more indication elements.
• the indication element may be moveably retained, preferably permanently retained, in the cap, in particular in the main body.
• the indication element may be retained inside the cap, in particular inside the main body.
• the indication element may be configured to be moved from a first position to a second position with respect to the main body.
• the cap may be configured to provide an information to a user.
• the information may indicate the state of use of the device.
• the information may indicate whether the cap was removed from the device at least once and, particularly, whether the cap was removed for the first time after the cap was connected to an element of the device.
• the term that the information indicates a state of use does not necessarily mean that the information indicates whether a dose of drug has been dispensed from the device. Rather, the information may indicate whether the user has removed the cap at least once and, thus, has reduced the sterility of the device as supplied by the manufacturer. By means of the information, the user may be able to distinguish between a new device and a device which is in use, e.g. a device from which the cap was removed at least once. The information indicated to the user by the cap may be changed when the indication element is moved from the first position into the second position.
• the indication element When the indication element is positioned in the first position, the indication element may be prevented from being viewed by the user, e.g. by means of the main body. In other words, the indication element may be hidden by the main body. Accordingly, the main body may be non-transparent.
• the indication element When the indication element is prevented from being viewed by the user, the user may know that the device has not been used yet and/or that the cap has not yet been removed from the device for the first time.
• the indication element When the indication element is positioned in the second position, the indication element may be visible to the user, e.g. through a window provided in the main body of the cap. Accordingly, when the indication element is moved from the first position into the second position, the indication element may become visible to the user.
• the user sees the indication element, he may know at once that the device is in use or has been used at least once and/or that the cap has been removed from the device at least once. Whichever position the indication element may have, the user can realize at once the state of use of the device when looking at the cap. This may help to increase user safety.
• a further aspect relates to a drug delivery device.
• the drug delivery device may comprise the previously described cap. Accordingly, features which are described herein above and below for the cap may also apply to the device and vice versa.
• the device may further comprise an interaction member.
• the interaction member may be adapted and arranged to interact with the indication element.
• the indication element may be moved from the first position to the second position when the interaction member mechanically cooperates with the indication element.
• the indication element may be moved from the first position into the second position only when the cap is removed from the device, in particular when the cap is removed from the device for the first time.
• the interaction member may be part of a component of the device.
• the interaction member When the cap is moved with respect to the device, e.g. when the cap is removed from the device, the interaction member may mechanically cooperate with the indication element. In this way, the information provided by the cap may change when the interaction member mechanically cooperates with the indication element.
• the user may know at once by viewing the cap whether the device is in use or not, in particular whether the cap has been removed at least once or not. This may help to increase user safety.
• a cap for a drug delivery device comprising a main body and at least one indication element which is moveably retained in the main body.
• the indication element is configured to be moved from a first position to a second position with respect to the main body, wherein an information indicated to a user by the cap is changed when the indication element is moved from the first position into the second position.
• a drug delivery device comprising the previously described cap and an interaction member
• the interaction member being adapted and arranged to interact with the indication element such that the indication element is moved from the first position to the second position when the interaction member mechanically cooperates with the indication element.
• Figure 1 schematically shows a perspective side view of a drug delivery device
• Figure 2 schematically shows a sectional side view of a part of the drug delivery device of Figure 1 ,
• Figure 3 schematically shows a sectional side view of a part of the drug delivery device of Figure 1 .
• the drug delivery device 1 comprises a housing 2.
• the drug delivery device 1 and/or a component thereof have a distal end and a proximal end.
• the distal end is indicated by arrow 8.
• the proximal end is indicated by arrow 9.
• the term "distal end” designates that end of the drug delivery device 1 or a component thereof which is or is to be arranged closest to a dispensing end of the drug delivery device 1 .
• proximal end designates that end of the system 1 or a component thereof which is or is to be arranged furthest away from the dispensing end of the system 1 .
• the distal end and the proximal end are spaced apart from one another in the direction of an axis 14.
• the axis may be the longitudinal axis of the drug delivery device 1 or elements thereof.
• the drug delivery device 1 comprises a drug retainer 3, 4.
• the drug retainer 3, 4 may comprise a cartridge holder 3.
• the drug delivery device 1 comprises a cartridge 4.
• the cartridge 4 is retained within the cartridge holder 3.
• the cartridge holder 3 stabilizes the position of the cartridge 4 mechanically.
• the drug retainer 3, 4 may comprise the cartridge 4.
• the cartridge holder 3 may be redundant.
• the cartridge holder 3 in particular the proximal end of the cartridge holder 3 is connectable, e.g. by a threaded engagement, to the housing 2 of the drug delivery device 1 .
• the cartridge 4 may be directly connected to the housing 2 (see, for example, Figure 1 ).
• the cartridge 4 contains a drug 10, preferably a plurality of doses of the drug 10.
• the drug 10 may be a liquid drug.
• drug preferably means a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active
• the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis, wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or
• the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1 ) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
• Insulin analogues are for example Gly(A21 ), Arg(B31 ), Arg(B32) human insulin;
• Lys(B3) Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
• Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N- palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl- LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N- palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; ⁇ 29- ⁇ -( ⁇ - carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( -carboxy
• Exendin-4 for example means Exendin-4(1 -39), a peptide of the sequence H-His-Gly-
• Exendin-4 derivatives are for example selected from the following list of compounds:
• H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1 -39)-Lys6-NH2,
• Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin,
• Somatropine Somatropin
• Desmopressin Terlipressin
• Gonadorelin Triptorelin
• Leuprorelin Buserelin
• Nafarelin Goserelin.
• a polysaccharide is for example a glucosanninoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned
• Antibodies are globular plasma proteins (-150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
• the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
• Ig immunoglobulin
• the Ig monomer is a "Y"-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-1 10 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two ⁇ sheets create a "sandwich" shape, held together by interactions between conserved cysteines and other charged amino acids.
• Ig heavy chain There are five types of mammalian Ig heavy chain denoted by ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
• the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
• Distinct heavy chains differ in size and composition; a and ⁇ contain approximately 450 amino acids and ⁇ approximately 500 amino acids, while ⁇ and ⁇ have approximately 550 amino acids.
• Each heavy chain has two regions, the constant region (CH) and the variable region (V H ).
• the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
• Heavy chains ⁇ , a and ⁇ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains ⁇ and ⁇ have a constant region composed of four immunoglobulin domains.
• the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
• the variable region of each heavy chain is approximately 1 10 amino acids long and is composed of a single Ig domain.
• a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
• CL constant domain
• VL variable domain
• the approximate length of a light chain is 21 1 to 217 amino acids.
• Each antibody contains two light chains that are always identical; only one type of light chain, K or ⁇ , is present per antibody in mammals.
• variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
• VL variable light
• VH variable heavy chain
• CDRs Complementarity Determining Regions
• an "antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
• Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab).
• the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
• F(ab')2 is divalent for antigen binding.
• the disulfide bond of F(ab')2 may be cleaved in order to obtain Fab'.
• the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
• Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCI or HBr salts.
• Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion
• R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
• R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
• solvates are for example hydrates.
• a bung 15 is moveably retained within the cartridge 4.
• the bung 15 seals the cartridge 4 proximally.
• the cartridge 4 may be a, e.g. pre-filled, cartridge. Movement of the bung 15 in the distal direction with respect to the cartridge 4 causes the drug 10 to be dispensed from the cartridge 4, provided that fluid communication between the distal end of the cartridge 4 and the environment, e.g. via a needle (not explicitly shown in the Figures), is established.
• the drug delivery device 1 may be a pen-type device, in particular a pen-type injector.
• the device 1 may be configured for dispensing fixed doses of the drug 10, i.e. doses which may not be varied by a user.
• the device 1 may be configured to dispensing variable doses of the drug 10, i.e. doses which can be varied by the user.
• the device 1 can be a re-usable device, which means that the cartridge 4 can be replaced, in particular during a reset operation, by a replacement reservoir for dispensing a plurality of doses from the replacement reservoir.
• the device 1 may be a disposable device. In this case, the cartridge 4 may not be replaced.
• the cartridge 4 may, for example, be non-releasably connected to the cartridge holder 3.
• the drug delivery device 1 may be a multidose device, i.e. a device configured for setting and dispensing a plurality of doses of the drug 10.
• the drug delivery device 1 comprises a drive mechanism.
• the drive mechanism 10 may be retained in the housing 2. The drive mechanism is used for setting and dispensing a dose of the drug 10.
• the drive mechanism comprises a piston rod 5.
• the piston rod 5 has a distal and a proximal end.
• the distal end of the piston rod 5 may be the end which is closest to the distal end of the drug delivery device 1 when the piston rod 5 has been introduced in the device 1 .
• the proximal end of the piston rod 5 may be the end which is furthest away from the distal end of the drug delivery device 1 when the piston rod 5 has been introduced in the device 1 .
• the piston rod 5 extends through the housing 2 of the device 1 .
• the piston rod 5 is designed to transfer axial movement through the drug delivery device 1 , for example for the purpose of delivering the drug 10.
• the piston rod 5 is axially displaceable in a dose delivery direction for delivering a dose of the drug 10.
• the dose delivery direction may be the distal direction with respect to the housing 2.
• the piston rod 5 is prevented from being axially displaced in a dose setting direction by mechanical cooperation with further components of the drive mechanism.
• the dose setting direction may be the proximal direction with respect to the housing 2.
• the piston rod 5 is prevented from being rotated with respect to the housing 2 when setting and when delivering a dose of the drug 10, for example, by mechanical cooperation with the housing 2.
• the drug delivery device 1 comprises a dose button 6 used for setting and/or dispensing a dose of the drug 10.
• the drug delivery device 1 comprises cap 7.
• the cap 7 is configured to cover at least parts of the device 1 .
• the cap 7 is configured to cover the dispensing end of the device 1 .
• the cap 7 is adapted and arranged to cover a needle (not explicitly shown in the Figures) attached to the distal end of the device 1 .
• the cap 7 is adapted and arranged to cover at least a part of the drug retainer 3, 4.
• the cap 7 covers the majority, such as 75% or more, of the drug retainer or the whole drug retainer 3, 4.
• the cap 7 can be connected, preferably releasably connected, to the drug retainer 3, 4.
• the cap 7 is connectable to the cartridge holder 3, for example.
• the cap 7 may be connectable to a proximal end section of the cartridge holder 3.
• the cap 7 may be connected to the cartridge holder 3 by a threaded connection or a snap-fit connection or a pin-groove cooperation.
• the cap 7 may be connectable directly to the cartridge 4.
• the cap 7 may be connected to the housing 2, in particular to a distal end section of the housing 2.
• Figures 2 and 3 schematically show a sectional side view of a part of the drug delivery device 1 of Figure 1 .
• the cap 7 comprises a main body 7A.
• the main body 7A is non-transparent.
• the main body 7A may be flexible.
• the main body 7A may be elastically deformable.
• the main body 7A comprises a closed end 7C.
• the closed end 7C is that end which is arranged closest to the dispensing end of the device 1 when the cap 7 is connected to the device 1 .
• the cap 7 comprises an open end 7D.
• the open end 7D is configured to receive at least a part of the device 1 , e.g. a part of the cartridge holder 3 or the complete cartridge holder 3.
• the open end 7D has a radial dimension suited to receive the cartridge holder 3 and/or the cartridge 4.
• the open end 7D is that end which is arranged furthest away from the dispensing end of the device 1 when the cap 7 is connected to the device 1 .
• the cap 7 comprises a display member 12.
• the cap 7 may comprise two, three or more display members 12.
• the display member 12 is configured to display information to the user.
• the display member 12 may be a window.
• the display member 12 may comprise an opening. The opening may be arranged in the surface of the main body 7A.
• the cap 7 comprises an indication element 1 1 .
• the indication element 1 1 is retained, preferably permanently retained, in the cap 7.
• the indication element 1 1 is not provided by the drug retainer 3, 4.
• the indication element 1 1 is provided by a component which is connectable to and moveable with respect to the drug retainer 3, 4, i.e. the cap 7.
• the indication element 1 1 is moveably retained in the cap 7, in particular in the main body 7A.
• the indication element 1 1 is moveable in the axial direction with respect to the main body 7A from a first position into a second position, which is described later on in more detail.
• the indication element 1 1 is arranged in the interior of the cap 7.
• the indication element 1 1 may be connected to the main body 7A,
• the indication element 1 1 is connected to the main body 7A via a clamping action which is established between the main body 7A and the indication element 1 1 .
• connections like a snap-fit connection, may also be applied for connecting the indication element 1 1 to the main body 7A.
• the connection is preferably strong enough to prevent accidental movement of the indication element 1 1 with respect to the main body 7A.
• the connection between the indication element 1 1 and the cap 7 is expediently a releasable stable connection which is stable until the connection is released deliberately.
• the indication element 1 1 comprises a locking section 1 1 A.
• the locking section 1 1 A in the depicted embodiment, comprises a smaller axial dimension than the holding section 1 1 B. In other words, the holding section 1 1 B is longer than the locking section 1 1 A.
• the locking section 1 1 A is arranged closer to the open end 7D of the cap 7 than the holding section 7B.
• the locking section 1 1 A is arranged closer to the second position of the indication element 1 1 than the holding section 1 1 B.
• the locking section 1 1A may comprise a protrusion of the indication element 1 1 .
• the locking section 1 1 A may protrude in the radial direction with respect to the holding section 1 1 B, preferably radially outwardly.
• the display member 12 is configured to receive the locking section 1 1A.
• the locking section 1 1A is configured to mechanically cooperate with the display member 12 for permanently locking the indication element 1 1 in the display member 12 when the indication element 1 1 is in the second position, which is described later on in detail.
• the indication element 1 1 When the indication element 1 1 is in the first position, the indication element 1 1 cannot be viewed by the user. In particular, the indication element 1 1 is prevented from being viewed by the user by means of the main body 7A. The indication element 1 1 is completely hidden by means of the main body 7A. In the first position (see Figure 2), the indication element 1 1 is biased. In particular, the indication element 1 1 is elastically deformed due to clamping the indication element 1 1 into the main body 7A. The indication element 1 1 is biased such that a force acts on the indication element 1 1 tending to move the indication element 1 1 in the radial outward direction with respect to the main body 7A. In the first position, the indication element 1 1 and, in particular, the holding section 1 1 B, projects into the interior of the cap 7.
• the indication element 1 1 projects into the interior such that there is an angle between the holding section 1 1 B and the inner surface of the main body 7A.
• the angle may be less than 90 degrees, preferably less than 45 degrees.
• the angle may be 15 degrees or more.
• the indication element 1 1 and, in particular the holding section 1 1 B may abut the blocking member 7B of the main body 7A. Accordingly, the first position may be the most distal position of the indication element 1 1 with respect to the main body 7A.
• the position may be temporarily stable such that the indication element 1 1 is moveable from the first position into the second position.
• the interaction member 13 may be a protrusion.
• the interaction member 13 may comprise a cam.
• the interaction member 13 is adapted and arranged to interact with the indication element 1 1 .
• the indication element 1 1 is moved from the first position to the second position.
• the axial position of the interaction member 13 with respect to the housing 2 depends on the axial position of the indication element 1 1 with respect to the housing 2 when the cap 7 is connected to the device 1 .
• the interaction member 13 comprises an axial position with respect to the housing 2 such that the indication element 1 1 passes along the interaction member 13 when the cap 7 is moved with respect to the device 1 for connecting or disconnecting the cap 7 to or from the device 1 .
• the interaction member 13 may be arranged in the distal end section of the device 1 , for example. Alternatively, the interaction member 13 can be arranged in the middle section or in the proximal end section of the device 1 depending on the axial position of the indication element 1 1 as described above. The axial position of the interaction member 13 may be more distal than the axial position of the locking section 1 1A of the indication element 1 1 .
• the cap 7 and, in particular, the indication element 1 1 and the display member 13 are configured for displaying an information to the user.
• the information may indicate the state of use of the device 1 .
• the information may indicate whether the cap 7 has been removed from the device 1 for the first time or not. Accordingly, with the term that the information indicates a state of use, it is not necessarily meant that the information indicates whether a dose of drug has already been dispensed from the device 1 .
• the information may indicate whether the user has removed the cap 7 from the device 1 at least once and, thus, has reduced the sterility of the device 1 as compared to the state as supplied by the manufacturer.
• the indication element 1 1 has a colour which is different from a colour of the cap.
• the indication element 1 1 may have a blue colour, for example, and the cap 7 may have a white colour, for example.
• the information provided to the user changes when the indication element 1 1 is moved from the first position into the second position. This is described in the following:
• the user For being able to use the device 1 for the first time, the user must remove the cap 7 from the device 1 .
• the indication element 1 1 is moved along the cartridge holder 3 (and/or the cartridge 4) in the distal direction with respect to the housing 2 and with respect to the interaction member 13.
• the indication element 1 1 is passed along the interaction member 13.
• the interaction member 13 mechanically cooperates with the locking section 1 1 A. This is possible as the indication element 1 1 projects into the interior of the cap 7 when the indication element 1 1 is in the first position, as described above.
• the interaction member 13 and the locking section 1 1A radially overlap when the indication element 1 1 is in the first position.
• the indication element 1 1 In the second position, the indication element 1 1 is permanently locked against movement due to mechanical cooperation with the display member 12. Accordingly, the indication element 1 1 cannot be moved from the second position back into the first position.
• the indication element 1 1 When the indication element 1 1 is in the second position, the indication element 1 1 no longer projects into the cap 7 such that it can mechanically cooperate with the interaction member 13. In particular, further mechanical cooperation between the indication element 1 1 and the interaction member 13 is prevented as there is a radial distance between the locking section 1 1A and the interaction member 13 when the indication element 1 1 is in the second position (see Figure 3).

Landscapes

• Health & Medical Sciences (AREA)
• Vascular Medicine (AREA)
• Engineering & Computer Science (AREA)
• Anesthesiology (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Infusion, Injection, And Reservoir Apparatuses (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=49083649

Family Applications (1)

Country Status (6)

Families Citing this family (1)

Citations (4)

Family Cites Families (40)

• 2013
  • 2013-08-15 JP JP2015527861A patent/JP6298056B2/ja active Active
  • 2013-08-15 CN CN201380043333.6A patent/CN104582769B/zh active Active
  • 2013-08-15 WO PCT/EP2013/067056 patent/WO2014029679A1/en not_active Ceased
  • 2013-08-15 EP EP13753835.1A patent/EP2885036B1/en active Active
  • 2013-08-15 US US14/421,356 patent/US10130778B2/en active Active
  • 2013-08-15 DK DK13753835.1T patent/DK2885036T3/da active

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events